Off-Label Use of Atypical Antipsychotics: An Update
Summary of Benefits: Atypical Antipsychotics for Major Depressive Disorder
Atypical antipsychotics increase the rate of response or remission when used to augment SSRIs and SNRIs. The strength of evidence for risperidone is moderate.
In monotherapy, quetiapine XR improves remission and response rates when compared with placebo, but olanzapine does not show efficacy. The strength of evidence in support of these findings is moderate.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | SSRI | SNRI | major depressive disorder | MDD | risperidone | ziprasidone | quetiapine | olanzapine | monotherapy
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.